CIK 0001781174
- Emerging growth company
Acrivon Therapeutics, Inc.
Sign in to watch- Ticker
- ACRV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 825125532
- Phone
- +1 617-207-8979
- Business address
- 480 ARSENAL WAY, SUITE 100, WATERTOWN, MA, 02472
- 4 Open-market sale 10% owner sold 16 shares at $12.93 ($207)
- 4 Exercise or conversion Chief Financial Officer acquired 9,500 shares (option exercise)
- 4 Open-market sale 10% owner sold 2,056 shares at $12.14 ($24,960)
- 4 Open-market sale 10% owner sold 5,893 shares at an average $12.29 ($72,412)
- 4 Exercise or conversion Chief Operating Officer acquired 9,225 shares (option exercise)
- 4 Exercise or conversion President and CEO acquired 33,605 shares (option exercise)
- 4 Open-market buy 10% owner bought 400,000 shares at $12.50 ($5,000,000)
- 4 Open-market buy Director bought 3,389,500 shares at $12.50 ($42,368,750)
- 4 Conversion 10% owner acquired 888,130 shares (conversion)
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award Chief Medical Officer acquired 20,030 shares (grant or award)
- 4 Grant or award Chief Operating Officer acquired 33,383 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 20,030 shares (grant or award)
- 4 Grant or award EVP - Business Operations acquired 1,524,947 shares (grant or award)
- 4 Grant or award President and CEO acquired 1,524,947 shares (grant or award)
- 3/A Insider 3/A
Page 10 of 11 · 211 filings